Plain Language Summaries

Standalone, citable summaries published in the Future Science Group journals written to be understood by a lay audience

Bladder, Kidney and Genitals

Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?

The PROSPER study showed that patients treated with enzalutamide lived longer than patients treated with placebo. But do patients’ traits affect the how people respond to treatment? This plain language summary published in Future Oncology provides an overview of a study examining this question.

Read the full article here.

The original article on which this summary is based is called ‘Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region’ and was originally published in the journal European Journal of Cancer. The original article can be read here.

Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

This plain language summary provides an overview of a real-world study using data from the Veterans Health Administration to look at the survival of Black men vs White men with advanced prostate cancer who are treated with two treatments, abiraterone or enzalutamide.

Read the full article here.

The original article on which this summary is based is called ‘Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer’ and was originally published in the journal Prostate Cancer and Prostatic Diseases . The original article can be read here.

Plain language summary of a study looking at heart muscle thickness and kidney function in women with Fabry disease who received agalsidase beta treatment

The new plain language summary of publication in Future Cardiology uses information from the Fabry Registry to understand the effects of agalsidase beta treatment in women with Fabry disease.

Read the full article here.

The original article on which this summary is based is called ‘Cardiomyopathy and kidney function in agalsidase beta-treated female Fabry patients: a pre-treatment vs. post-treatment analysis’ and was originally published in the journal ESC Heart Failure. The original article can be read here.

Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer

The ongoing TALAPRO-2 study is looking at the combination of two medicines called talazoparib and enzalutamide as a first treatment in adult men with metastatic castration-resistant prostate cancer. This plain language summary provides an overview of the study protocol published in Future Oncology.

Read the full article here.

The original article on which this summary is based is called ‘Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design’ and was originally published in the journal Future Oncology. The original article can be read here.

A plain language summary of the likelihood of symptom relief for patients taking fesoterodine for overactive bladder

In this plain language summary published in Journal of Comparative Effectiveness Research, learn about a study that looked at how likely it is that individual people with overactive bladder will achieve a certain level of improvement in their symptoms when taking fesoterodine.

Read the full article here.

The original article on which this summary is based is called ‘What are the chances of improvement or cure from overactive bladder? A pooled responder analysis of efficacy and treatment emergent adverse events following treatment with fesoterodine’ and was originally published in the journal Neurourology and Urodynamics here.